The Con Argument

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 2, 2010, Pages 129-132

  Camilleri, Michael ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE;

BLOATING; CELIAC DISEASE; CONSTIPATION; DIARRHEA; EDITORIAL; GASTROINTESTINAL PAIN; GLUTEN FREE DIET; HEALTH SURVEY; HUMAN; INTESTINE BIOPSY; IRRITABLE COLON; MICROSCOPIC COLITIS; PHENOTYPE;

EID: 75349083538     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2009.10.009     Document Type: Editorial

References (51)

1. Quigley E.M. The "con" case. The Rome process and functional gastrointestinal disorders: the barbarians are at the gate!. Neurogastroenterol Motil 19 (2007) 793-797
2. Halder S.L., Locke III G.R., Schleck C.D., et al. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology 133 (2007) 799-807
3. Locke III G.R., Zinsmeister A.R., Fett S.L., et al. Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil 17 (2005) 29-34
4. Wong R.K., Palsson O.S., Turner M.J., et al. Are functional constipation (FC) and constipation subtype irritable bowel syndrome (IBS-C) different entities when diagnosed by ROME III criteria?. Gastroenterology 136 Suppl 1 (2009) A-376
5. Müller-Lissner S.A., Fumagalli I., Bardhan K.D., et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 15 (2001) 1655-1666
6. Johanson J.F., Wald A., Tougas G., et al. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2 (2004) 796-805
7. Johanson J.F., Drossman D.A., Panas R., et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 27 (2008) 685-696
8. Drossman D.A., Chey W.D., Johanson J.F., et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 29 (2009) 329-341
9. Johnston J.M., Kurtz C.B., Drossman D.A., et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 104 (2009) 125-132
10. Andresen V., Camilleri M., Busciglio I.A., et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 133 (2007) 761-768
11. Camilleri M., and Chang L. Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. Gastroenterology 135 (2008) 1877-1891
12. Palsson O.S., Turner M.J., Levy R.L., et al. The Rome III functional constipation criteria miss 80% of clinical constipation cases. Gastroenterology 136 Suppl 1 (2009) A-378
13. Bharucha A.E., Locke G.R., Zinsmeister A.R., et al. Differences between painless and painful constipation among community women. Am J Gastroenterol 101 (2006) 604-612
14. Bharucha A.E., Seide B.M., Zinsmeister A.R., et al. Insights into normal and disordered bowel habits form bowel diaries. Am J Gastroenterol 103 (2008) 692-698
15. Rangnekar A.S., Morgan D., Knechtges P., et al. Complaints suggestive of irritable bowel syndrome are common in patients with puborectalis dyssynergia: an under-recognized overlap syndrome. Gastroenterology 134 (2008) A-423
16. Chiarioni G., Salandini L., and Whitehead W.E. Biofeedback benefits only patients with outlet dysfunction, not patients with isolated slow transit constipation. Gastroenterology 129 (2005) 86-97
17. Voderholzer W.A., Schatke W., Mühldorfer B.E., et al. Clinical response to dietary fiber treatment of chronic constipation. Am J Gastroenterol 92 (1997) 95-98
18. Heymen S., Scarlett Y., Jones K., et al. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. Dis Colon Rectum 50 (2007) 428-441
19. Rao S.S., Seaton K., Miller M., et al. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. Clin Gastroenterol Hepatol 5 (2007) 331-338
20. Chiarioni G., Whitehead W.E., Pezza V., et al. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology 130 (2006) 657-664
21. Lembo A., and Camilleri M. Chronic constipation. N Engl J Med 349 (2003) 1360-1368
22. Minguez M., Herreros B., Sanchiz V., et al. Predictive value of the balloon expulsion test for excluding the diagnosis of pelvic floor dyssynergia in constipation. Gastroenterology 126 (2004) 57-62
23. Harewood G.C., Coulie B., Camilleri M., et al. Descending perineum syndrome: audit of clinical and laboratory features and outcome of pelvic floor retraining. Am J Gastroenterol 94 (1999) 126-130
24. Palsson O.S., Turner M.J., Baggish J.S., et al. Characterizing diarrhea in irritable bowel syndrome (IBS). Gastroenterology 136 Suppl 1 (2009) M1223
25. Hofmann A.F., and Hagey L.R. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 65 (2008) 2461-2483
26. Thaysen E.H., and Pedersen L. Diarrhoea associated with idiopathic bile acid malabsorption. Fact or fantasy?. Dan Med Bull 20 (1973) 174-177
27. Sinha L., Liston R., Testa H.J., et al. Idiopathic bile acid malabsorption: qualitative and quantitative clinical features and response to cholestyramine. Aliment Pharmacol Ther 12 (1998) 839-844
28. Smith M.J., Cherian P., Raju G.S., et al. Bile acid malabsorption in persistent diarrhoea. J R Coll Physicians Lond 34 (2000) 448-451
29. Fernández-Bañares F., Esteve M., Salas A., et al. Systematic evaluation of the causes of chronic watery diarrhea with functional characteristics. Am J Gastroenterol 102 (2007) 2520-2528
30. Srinivas M., Basumani P., Dawson B., et al. Bile acid malabsorption (BAM) and ileal histology in diarrhea-predominant irritable bowel syndrome (D-IBS). Gastroenterology 132 (2007) A-1
31. Sciarretta G., Fagioli G., Furno A., et al. 75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit. Gut 28 (1987) 970-975
32. Sauter G.H., Munzing W., von Ritter C., et al. Bile acid malabsorption as a cause of chronic diarrhea: diagnostic value of 7 alpha-hydroxy-4-cholester-3-one in serum. Dig Dis Sci 44 (1999) 14-19
33. Camilleri M., Nadeau A., Tremaine W.J., et al. Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. Neurogastroenterol Motil 21 (2009) 734-743
34. Locke III G.R., Murray J.A., Zinsmeister A.R., et al. Celiac disease serology in irritable bowel syndrome and dyspepsia: a population-based case-control study. Mayo Clin Prod 79 (2004) 476-482
35. Spiegel B.M., DeRosa V.P., Gralnek I.M., et al. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 126 (2004) 1721-1732
36. Ford A.C., Chey W.D., Talley N.J., et al. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med 169 (2009) 651-658
37. Cooper B.T., Holmes G.K., Ferguson R., et al. Gluten-sensitive diarrhea: evidence of celiac disease. Gastroenterology 81 (1981) 192-194
38. Wahnschaffe U., Schulzke J.D., Zeitz M., et al. Predictors of clinical response to gluten-free diet in patients, diagnoses with diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 5 (2007) 844-850
39. Verdu E.F., Huang X., Natividad J., et al. Gliadin-dependent neuromuscular and epithelial secretory responses in gluten-sensitive HLA-DQ8 transgenic mice. Am J Physiol 294 (2008) G217-G225
40. Limsui D., Pardi D.S., Camilleri M., et al. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Nat Clin Pract Gastroenterol Hepatol 4 (2007) 304-305
41. Chande N., McDonald J.W., and Macdonald J.K. Interventions for treating lymphocytic colitis. Cochrane Database Syst Rev (2008) CD006096
42. Metcalf A.M., Phillips S.F., Zinsmeister A.R., et al. Simplified assessment of segmental colonic transit. Gastroenterology 92 (1987) 40-47
43. Charles F., Camilleri M., Phillips S.F., et al. Scintigraphy of the whole gut: clinical evaluation of transit disorders. Mayo Clin Proc 70 (1995) 113-118
44. Camilleri M., McKinzie S., Busciglio I., et al. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 6 (2008) 772-781
45. Bonapace E.S., Maurer A.H., Davidoff S., et al. Whole gut transit scintigraphy in the clinical evaluation of patients with upper and lower gastrointestinal symptoms. Am J Gastroenterol 95 (2000) 2838-2847
46. Sadik R., Stotzer P.O., Simrén M., et al. Gastrointestinal transit abnormalities are frequently detected in patients with unexplained GI symptoms at a tertiary centre. Neurogastroenterol Motil 20 (2008) 197-205
47. Agrawal A., Houghton L.A., Reilly B., et al. Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit. Am J Gastroenterol 104 (2009) 1998-2004
48. Agrawal A., Houghton L.A., Lea R., et al. Bloating and distention in irritable bowel syndrome: the role of visceral sensation. Gastroenterology 134 (2008) 1882-1889
49. Houghton L.A., Lea R., Agrawal A., et al. Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit. Gastroenterology 131 (2006) 1003-1010
50. Serra J., Azpiroz F., and Malagelada J.R. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 48 (2001) 14-19
51. Owens D.M., Nelson D.K., and Talley N.J. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med 122 (1995) 107-112